Financings in Brief: Genzyme
This article was originally published in The Gray Sheet
Genzyme: Firm's Genzyme Tissue Repair division receives $10 mil. "for general corporate purposes" from sister division Genzyme General "in exchange for an increase of one million Tissue Repair designated shares," the firm states. The designated shares "are not issued or outstanding" but may be held or sold by the Genzyme board of directors "from time to time for the benefit of Genzyme General without allocating any consideration to Genzyme Tissue Repair," or may be distributed "as a stock dividend to holders of Genzyme General common stock." Parent firm Genzyme retains an option, valid until June 15, 1998, to "allocate an additional $10 mil." from Genzyme General to Genzyme Tissue Repair "in exchange for an increase in Tissue Repair designated shares at the rate of $10 per share," Genzyme says...
You may also be interested in...
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.